Natasha Halasa

Director, Vanderbilt Infection Surveillance and Protection Research (VISPR) Program · Vanderbilt University Medical Center

Credentials: · · · ·

History

Immunogenicity and Safety of High-Dose vs. Standard-Dose Influenza Vaccines Administered Over Consecutive Seasons to Lung Transplant Recipients
National Institute of Allergy and Infectious Diseases · U01
Contact PI · $888K · Vanderbilt University Medical Center
2026–2031
ECHO Laboratory Core at Vanderbilt for Integrated Sample Biobanking and Processing
NIH Office of the Director · U24
Contact PI · $11.7M · Vanderbilt University Medical Center
2023–2030
Comparison of High vs. Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant Recipients
National Institute of Allergy and Infectious Diseases · U01
Contact PI · $6.7M · Vanderbilt University Medical Center
2023–2028
IP21-002 Enhanced Surveillance for New Vaccine Preventable Diseases
NCIRD · U01
Contact PI · $11.1M · Vanderbilt University Medical Center
2021–2027

High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
Principal investigator · Active not recruiting · Phase 2
Vanderbilt University Medical Center
2022–2027
COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C
Principal investigator · Completed
National Institute of Allergy and Infectious Diseases (NIAID)
2020–2023
High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant
Principal investigator · Completed · Phase 2
Vanderbilt-Ingram Cancer Center
2016–2024
Standard Dose Versus High-Dose Inactivated Flu Vaccine in Pediatric Solid Organ Transplant Patients
Principal investigator · Completed · Phase 1
Vanderbilt University
2011–2012